Major pathological response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy. Issue 5 (23rd January 2023)

• Record Type: Journal Article
• Authors: Xia, Lang; Guo, Junhong; E, Haoran; Zhang, Wei; Huang, Yan; Zhang, Liping; Zhao, Deping; Xie, Dong; Wu, Chunyan; Hou, Likun
• Is Part Of: Histopathology. Volume 82:Issue 5(2023)
• Page Start: 691
• Page End: 703
• Publication Date: 2023-01-23
• Subjects: chemotherapy -- lung adenocarcinoma -- major pathological response -- neoadjuvant therapy -- targeted therapy; Histology, Pathological -- Periodicals; 611.018
• DOI: 10.1111/his.14855
• Languages: English
• ISSNs: 0309-0167

Abstract

Abstract : Aims: For non‐small‐cell lung cancer (NSCLC) patients receiving neoadjuvant therapy, the major pathological response (MPR) is defined as the percentage of residual viable tumour cells (%RVT) in the tumour bed of no more than 10%. It has been proposed as a predictor of survival in neoadjuvant therapy‐treated cohorts. Nonetheless, the significance of %RVT in the pathological assessment of lung adenocarcinoma cohorts remains undetermined. Methods and results: Overall, 152 lung adenocarcinoma patients were included in this retrospective study, among whom 67 received neoadjuvant targeted therapy and 85 received neoadjuvant chemotherapy. Clinicopathological characteristics, neoadjuvant treatment response and survival status were investigated. The routinely adopted standard for MPR (%RVT ≤ 10%) failed to differentiate prognosis in the lung adenocarcinoma population. For the neoadjuvant chemotherapy cohort, the optimal %RVT cut‐off value of RFS was 60%. However, this cut‐off value was clinically insignificant in the neoadjuvant targeted‐therapy cohort. Hence, for these patients, we built a nomogram model including high‐grade patterns and ypN stage to predict disease recurrence, demonstrating high efficacy (a bootstrap‐corrected C‐index of 0.731). Conclusions: %RVT served as a strong indicator of the prognosis of lung adenocarcinoma in patients receiving neoadjuvant chemotherapy but not neoadjuvant targeted therapy. Residual high‐grade pathological patterns might substitute MPR in prognostic evaluation of lung adenocarcinoma post‐targeted therapy. Abstract : This study demonstrated that the optimal cutoff value of the percentage of residual viable tumor cells (%RVT) in lung adenocarcinoma (LUAD) post neoadjuvant chemotherapy existed (60% for RFS, and 70% for OS), but was not obtained in neoadjuvant targeted therapy cohort. High‐grade patterns and ypN stage might assist the prognostic evaluation of LUAD treated with neoadjuvant targeted therapy.